Fragment screens provide an information-rich starting point for designing derivative compounds in structure-based drug discovery. However, derivatives in the fragment-to-hit stage are typically designed from only one or a few fragments, risking premature convergence on an unproductive series and dramatically limiting e...
K. Fieseler, M. Winokan, Joseph A. Morrone et al.· Chemical Science· 0 citations
Efficient drug discovery workflows ideally generate data that directly address key translational milestones, including confirmation of target engagement and binding pose, structure–activity relationships (SARs), and biological relevance, within rapid and resource-efficient experimental cycles. Here, we describe a data-...
D. Muñoz-Reyes, K. Fieseler, M. Winokan et al.· Chemical Science· 0 citations
High-quality experimental datasets that link protein–ligand structures with binding affinity data are essential for developing and evaluating structure-based machine learning methods. To help address this need, we established OpenBind as an open-science initiative to generate large-scale experimental datasets for struc...
Jochem Nelen, Omeir Khan, Etowah Adams et al.· bioRxiv· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.